CD8A and B-cell chronic lymphocytic leukemia: For instance, in a phase I clinical trial, a peptide vaccination emulsified in IFA successfully elicited leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia (CLL) [107].